cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Poseida Therapeutics Inc
3 own
2 watching
Current Price
$0
$0.04
(1.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
209.96M
52-Week High
52-Week High
8.82
52-Week Low
52-Week Low
1.95
Average Volume
Average Volume
0.02M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization209.96M
icon52-Week High8.82
icon52-Week Low1.95
iconAverage Volume0.02M
iconDividend Yield--
iconP/E Ratio--
What does the Poseida Therapeutics Inc do?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
Read More
How much money does Poseida Therapeutics Inc make?
News & Events about Poseida Therapeutics Inc.
PR Newswire
5 months ago
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition PR...
Ticker Report
6 months ago
Poseida Therapeutics, Inc. (NASDAQ:PSTX Get Rating) Analysts at William Blair decreased their FY2023 EPS estimates for Poseida Therapeutics in a research note issued on Thursday, November 10th. William Blair analyst R. Prasad now expects that the company will post earnings of $0.89 ...
Zolmax
6 months ago
Poseida Therapeutics, Inc. (NASDAQ:PSTX Get Rating) William Blair dropped their FY2023 earnings per share estimates for shares of Poseida Therapeutics in a research report issued to clients and investors on Thursday, November 10th. William Blair analyst R. Prasad now forecasts that the company will ...
PR Newswire
6 months ago
Poseida Therapeutics to Present at Two Upcoming Investor Conferences Poseida Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 8, 2022 SAN DIEGO, Nov. 8, 2022 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company...
Frequently Asked Questions
Frequently Asked Questions
What is Poseida Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Poseida Therapeutics Inc shares?
plus_minus_icon
How can I buy Poseida Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Poseida Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Poseida Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Poseida Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Poseida Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Poseida Therapeutics Inc?
plus_minus_icon
What percentage is Poseida Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Poseida Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.04
(1.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$17.11
$0.05 (0.26 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$5.71
$-0.05 (-0.87 %)
FOGHORN THERAPEUTICS INC
FOGHORN THERAPEUTICS INC
$7.43
$0.33 (4.63 %)
Athira Pharma Inc
Athira Pharma Inc
$3.01
$-0.01 (-0.33 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
TARSUS PHARMACEUTICALS INC
TARSUS PHARMACEUTICALS INC
$17.11
$0.05 (0.26 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$5.71
$-0.05 (-0.87 %)
FOGHORN THERAPEUTICS INC
FOGHORN THERAPEUTICS INC
$7.43
$0.33 (4.63 %)
Athira Pharma Inc
Athira Pharma Inc
$3.01
$-0.01 (-0.33 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00